Physician profile
John Castaneda
NPI 1467416628
$5,461.90
in general payments reported to CMS, 2019-2025
38 companies · $738 in 2025
The $738 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $657 · 2020: $154 · 2021: $569 · 2022: $944 · 2023: $1,340 · 2024: $1,060 · 2025: $738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,052 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,052.31 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,013.82 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $892.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $408.85 | 2020-2025 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $394.73 | 2019-2024 | Andexxa, Farxiga, Fasenra |
| Amgen INC. | $298.85 | 2019-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.68 | 2019-2025 | Jardiance, Synjardy |
| Pfizer INC. | $193.90 | 2020-2025 | |
| Abbott Laboratories | $192.73 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $182.49 | 2023-2025 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $161.92 | 2019-2025 | Trintellix |
| Glaxosmithkline, LLC. | $134.10 | 2019-2025 | Trelegy Ellipta |
| Axsome Therapeutics, INC. | $130.64 | 2023-2025 | Auvelity, Symbravo |
| Sanofi-Aventis U.S. LLC | $123.74 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $114.29 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $87.17 | 2019-2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Castaneda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.